Information Provided By:
Fly News Breaks for December 8, 2019
ARWR
Dec 8, 2019 | 20:13 EDT
Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead Pharmaceuticals to $80 from $72 and reiterates an Overweight rating on the shares. Arrowhead expects to have three pivotal Phase III trials underway in 2020, and the company has pro forma cash of $554M to advance its wholly-owned TRiM pipeline, Tenthoff tells investors in a research note.
News For ARWR From the Last 2 Days
There are no results for your query ARWR
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.